MannKind stock surges on United Therapeutics partnership deal By Investing.com

MannKind shares jumped 38.3% after announcing development of ralinepag DPI for United Therapeutics, with the company eligible for up to $35 million in milestones plus 10% royalties on commercial sales. United Therapeutics also made an additional $5 million payment in April to accelerate development, and it plans to lead global development and commercialization. The collaboration extends a prior relationship that produced Tyvaso DPI, which generated $1.3 billion in 2025 revenue.

Analysis

This is less a single-product rerating than an embedded option on United Therapeutics’ franchise durability. The key second-order effect is that a successful DPI version of ralinepag would extend UT's inhaled-prostacyclin moat into a follow-on asset before the current growth engine fully matures, which lowers perceived patent-cliff risk and supports a higher terminal multiple. For MNKD, the market is likely beginning to price a “platform toll collector” narrative: the company can monetize formulation expertise with limited commercial burden, which is attractive because milestone/royalty economics can re-rate faster than operating earnings.

The more interesting winner is UTHR, not MNKD. If management can migrate a future PAH launch into a DPI format, it may improve adherence and device convenience versus oral or more complex delivery pathways, potentially widening prescriber preference and making payer re-contracting easier by reinforcing a differentiated ecosystem. The risk is execution timing: this is a multi-year catalyst with binary regulatory and clinical dependencies, so the current move likely front-runs actual cash flow by 12-24 months and may fade if the market starts discounting development-stage uncertainty rather than commercialization value.

Consensus is probably underestimating how much this validates the prior collaboration model, but overestimating near-term monetization. MNKD’s upside is capped until milestone cadence becomes visible; if that stalls, the stock can give back a large portion of a single-day rerating quickly. The cleaner setup is a relative-value expression: own the asset with the most durable economics and hedge the higher-beta speculation, especially if biotech risk appetite weakens or broader small-cap healthcare multiples compress.

Key Decisions for Investors

• Long UTHR / short MNKD as a 3-6 month pair trade: own the company with the clearest commercial optionality and hedge the more valuation-sensitive collaborator; target ~1.5-2.0x spread expansion if the market reprices development economics more rationally.
• Buy MNKD only on a pullback of 10-15% from the spike, with a 6-12 month horizon: the trade works if investors start assigning value to recurring royalty optionality, but downside is high if no additional milestone disclosure arrives.
• Add UTHR on any post-event consolidation over 2-8 weeks: best risk/reward is owning the franchise extension story before sell-side models fully capitalize the follow-on pipeline value.
• Use short-dated calls on MNKD only for event-driven momentum, not investment exposure: upside can persist for days to weeks, but theta risk is high if the market realizes this is not an immediate revenue step-up.
• Watch for a confirmation catalyst around regulatory or trial-design updates in the next 6-18 months; absent that, trim MNKD into strength and keep UTHR as the core holding.